-- Earnings Flash (VBIV) VBI VACCINES Posts Q2 Revenue $346,000
8:01AM ET 8/08/2022 MT Newswires...
VBI Vaccines (VBIV) said Wednesday it has received orphan drug designation from the US Food and Drug Administration for VBI-1901, which is intended for the...
VBI Vaccines (VBIV) said Monday updated tumor response and overall survival data from a phase 2a trial of VBI-1901 cancer vaccine candidate for recurrent...
VBI Vaccines (VBIV) said Wednesday it has secured marketing approval by the UK Medicines and Healthcare Products Regulatory Agency for its hepatitis B...
Address | 160 2nd Street Cambridge, Massachusetts 02142 |
Phone | +1.617.830.3031 |
Number of Employees | 112 |
President, Chief Executive Officer & Director | Jeff Baxter |
CFO, Director & Head-Business Development | Christopher McNulty |
Chief Medical Officer | Francisco Diaz-Mitoma |
Chief Scientific Officer | David Evander Anderson |
Price Open | $1.13 |
Previous Close | $1.10 |
52 Week Range | $0.64 - 3.81 |
Market Capitalization | $315.1 M |
Shares Outstanding | 258.3 M |
Sector | Health Technology |
Industry | Biotechnology | Next Earnings Announcement | 11/14/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | N/A |
Earnings per Share | -$0.39 |
Beta vs. S&P 500 | N/A |
Revenue | $3.4 M |
Net Profit Margin | -15,391.36% |
Return on Equity | -75.37% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |